At NUVISAN, we offer all necessary functions covering lead discovery, computational and medicinal chemistry, in vitro and in vivo pharmacology, DMPK, and toxicology to validate concepts, identify new chemical matter, and build value for pharma/biotech/VC.
NUVISAN presents the result of the Cache Challenge #2 : CA(t)CHEing Hits for NSP13 - Rapid Hit Identification Through Virtual Screening
NUVISAN presents a pathway high-throughput screen and subsequent target deconvolution studies that identified a potent YAP/TAZ inhibitor and PGGT1B as its direct target.
Immuno-oncology has revolutionized cancer treatment by harnessing the immune system to target and eliminate tumor cells. The development of novel therapeutics requires robust preclinical models and immune cell assays. In this study, we employed a combination of full spectrum flow cytometry (Cytek®) and spatial profiling by Immunohistochemistry (IHC) to investigate the impact of Immune checkpoint inhibitors, anti-PD1 and anti-CTLA4 treatments on the 4T1 breast cancer model.
At NUVISAN, we offer high-throughput 3D cell culture systems for compound screening with advanced models.
Selective covalent inverse-agonists were identified by high-throughput screening against the human hormone receptor PPARG (peroxisomeproliferator activated receptor gamma), PPARG represents a potential target for a new generation of anti-cancer therapeutics, especially in bladder and pancreatic cancers.
In lab settings, mice are often taken out of cages for cleaning and procedures. Using non-aversive methods, like tunnel-handling, is a better way to handle them than the traditional fixation. Studies show that this approach reduces stress even during experiments. This study aimed to implement this method in a large mouse breeding facility over 9 weeks, starting at weaning.
Rabbits are social but can become aggressive when mature or introduced to new groups. To keep them happy and prevent boredom, they need space and cage enrichments. A study evaluated different housing options for their well-being and suitability.
Immunosenescence, the age-related decline in immune function, contributes to disease susceptibility. At NUVISAN, we utilise advanced spectrum cytometry which enables comprehensive analysis of immune cell markers to reveal complexities in aging of cellular composition, activation, and function.
Using spectral cytometry, NUVISAN achieves high-resolution immunophenotyping across species, optimizing sample utilization and extracting essential immunological insights.
At NUVISAN, we address the diverse immune and non-immune elements within tumor microenvironments, crucial for treatment response. Personalized therapies depend on grasping this diversity through techniques like immune profiling, RNA-Seq, IHC, flow cytometry, and functional assays.
NUVISAN presents available model systems and cell engineering tools and its capabilities with induced pluripotent human stem cells (iPSCs), tumor spheroids, cell-tissue interactions, and organoids.
NUVISAN presents the identification of novel positive and negative regulators of YAP1/TAZ in MDA-MB-231 breast cancer cells via a pooled whole genome CRISPR/Cas9 screen.
NUVISAN is supporting the global Target 2035 initiative set up by the Structural Genomics Consortium (SGC) and others, which aims to develop pharmacological modulators for each human protein.
NUVISAN establishment of high-throughput fluorescent in situ hybridization screening to identify novel compounds that modulate oncogenic lncNRA MALAT1 in a cellular setting.
